PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20875380-10	2010	Ezetimibe decreased HDL-SAA by 43 % (to 32 +- 36 microg/ml), and this inhibitory effect was exclusively attributable to a 72% reduction in HDL3-SAA in response to the ezetimibe treatment.	Ezetimibe	0-9	serum amyloid A1 cluster	Homo sapiens	24-27	
20875380-10	2010	Ezetimibe decreased HDL-SAA by 43 % (to 32 +- 36 microg/ml), and this inhibitory effect was exclusively attributable to a 72% reduction in HDL3-SAA in response to the ezetimibe treatment.	Ezetimibe	0-9	serum amyloid A1 cluster	Homo sapiens	144-147	
20875380-10	2010	Ezetimibe decreased HDL-SAA by 43 % (to 32 +- 36 microg/ml), and this inhibitory effect was exclusively attributable to a 72% reduction in HDL3-SAA in response to the ezetimibe treatment.	Ezetimibe	167-176	serum amyloid A1 cluster	Homo sapiens	144-147	
20875380-12	2010	CONCLUSIONS: Ezetimibe treatment decreased "inflammatory" (SAA-containing) HDL3, and may thus have restored the anti-atherogenic function of HDL particles in ESRD patients.	Ezetimibe	13-22	serum amyloid A1 cluster	Homo sapiens	59-62